Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBU
3701
DELISTED
Brookfield Business Partners
BBU
| $590K | ﹤0.01% |
16,751
+14,817
| +766% | +$508K |
|
3702
Vaalco Energy
EGY
$586M
| $588K | ﹤0.01% |
161,486
+15,625
| +11% | +$57.8K |
|
3703
Spok Holdings
SPOK
$231M
| $587K | ﹤0.01% |
44,520
+2,313
| +5% | +$32.8K |
|
3704
Vanguard Dividend Appreciation ETF
VIG
$115B
| $587K | ﹤0.01% |
2,670
-4,470
| -63% | -$977K |
|
|
STRZ
3705
Starz Entertainment Corp
STRZ
$471M
| $586K | ﹤0.01% |
50,106
+14,006
| +39% | +$160K |
|
|
AII
3706
American Integrity Insurance
AII
$459M
| $586K | ﹤0.01% |
28,121
+16,773
| +148% | +$373K |
|
|
FPI
3707
Farmland Partners
FPI
$432M
| $586K | ﹤0.01% |
60,441
+2,051
| +4% | +$20.6K |
|
3708
Chunghwa Telecom
CHT
$32.8B
| $585K | ﹤0.01% |
+14,036
| New | +$593K |
|
3709
West Bancorporation
WTBA
$506M
| $585K | ﹤0.01% |
26,341
+5,104
| +24% | +$110K |
|
3710
First Western Financial
MYFW
$307M
| $584K | ﹤0.01% |
21,788
+1,244
| +6% | +$29.7K |
|
3711
Ribbon Communications
RBBN
$376M
| $583K | ﹤0.01% |
202,461
+47,690
| +31% | +$154K |
|
3712
Intrepid Potash
IPI
$485M
| $583K | ﹤0.01% |
21,012
+5,449
| +35% | +$146K |
|
3713
Lineage Cell Therapeutics
LCTX
$273M
| $582K | ﹤0.01% |
348,510
+348,509
| +34,850,900% | +$603K |
|
3714
Brookfield Renewable
BEP
$10.3B
| $580K | ﹤0.01% |
21,499
+5,122
| +31% | +$146K |
|
3715
Bridgewater Bancshares
BWB
$617M
| $579K | ﹤0.01% |
33,013
+3,137
| +11% | +$54.4K |
|
3716
CALL
Zoom
ZM
$31.1B
| $578K | ﹤0.01% |
6,700
| – | – |
|
3717
Reynolds Consumer Products
REYN
$5.59B
| $575K | ﹤0.01% |
25,107
+23,149
| +1,182% | +$558K |
|
|
BRCB
3718
Black Rock Coffee Bar Inc
BRCB
$191M
| $573K | ﹤0.01% |
25,767
+15,643
| +155% | +$363K |
|
3719
Fidelity D&D Bancorp
FDBC
$319M
| $572K | ﹤0.01% |
13,141
-10
| -0.1% | -$443 |
|
3720
JFrog
FROG
$10.7B
| $571K | ﹤0.01% |
9,145
+8,989
| +5,762% | +$511K |
|
|
CVGW
3721
DELISTED
Calavo Growers
CVGW
| $571K | ﹤0.01% |
26,248
+2,288
| +10% | +$50.7K |
|
|
NEXN
3722
Nexxen International
NEXN
$578M
| $571K | ﹤0.01% |
87,288
+288
| +0.3% | +$2.14K |
|
3723
ADC Therapeutics
ADCT
$131M
| $570K | ﹤0.01% |
161,386
+30,926
| +24% | +$125K |
|
3724
iShares Russell 1000 Value ETF
IWD
$84.4B
| $568K | ﹤0.01% |
+2,700
| New | +$558K |
|
3725
Editas Medicine
EDIT
$441M
| $566K | ﹤0.01% |
276,262
+89,212
| +48% | +$258K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.